Abstract
The goal of treatment for acute hepatitis C patients is to eradicate the virus in the early phase of infection, thus preventing progression to chronicity. Early interferon (IFN) monotherapy has been shown to significantly reduce this risk, and therefore it has been recommended by international guidelines. To date, there is no standard treatment for the acute form of hepatitis C because available studies refer to small patient series receiving a variety of treatment regimens administered at varying time-points after onset of acute infection. Nevertheless, on the basis of published data, pegylated IFN monotherapy seems to offer the best therapeutic option because it is as effective as standard IFN monotherapy, and more convenient for the patient. Delaying treatment for 3 months after disease onset does not appear to reduce treatment efficacy and allows the identification of subjects with spontaneous resolution. It remains to be defined if an immediate treatment is more effective in patients with asymptomatic disease or those with genotype 1b. The optimal duration of Peg-IFN monotherapy should be 6 months. The efficacy of a 3-month course is under evaluation, especially for patients with clearance of HCV viremia within the first 4 weeks of therapy. There is no evidence that Peg-IFN/ribavirin combination therapy is more effective than Peg- IFN monotherapy, thus combination therapy might represent an alternative for patients who do not respond to IFN monotherapy or for HIV/HCV co-infected patients. Ongoing randomized controlled clinical trials should focus on unresolved questions and definitely establish the optimal treatment for acute hepatitis C.
Keywords: Acute hepatitis C, hepatitis C virus, pegylated interferon, antiviral therapy
Current Pharmaceutical Design
Title: Therapy of Acute Hepatitis C: A Review of Literature
Volume: 14 Issue: 17
Author(s): T. Santantonio and M. Fasano
Affiliation:
Keywords: Acute hepatitis C, hepatitis C virus, pegylated interferon, antiviral therapy
Abstract: The goal of treatment for acute hepatitis C patients is to eradicate the virus in the early phase of infection, thus preventing progression to chronicity. Early interferon (IFN) monotherapy has been shown to significantly reduce this risk, and therefore it has been recommended by international guidelines. To date, there is no standard treatment for the acute form of hepatitis C because available studies refer to small patient series receiving a variety of treatment regimens administered at varying time-points after onset of acute infection. Nevertheless, on the basis of published data, pegylated IFN monotherapy seems to offer the best therapeutic option because it is as effective as standard IFN monotherapy, and more convenient for the patient. Delaying treatment for 3 months after disease onset does not appear to reduce treatment efficacy and allows the identification of subjects with spontaneous resolution. It remains to be defined if an immediate treatment is more effective in patients with asymptomatic disease or those with genotype 1b. The optimal duration of Peg-IFN monotherapy should be 6 months. The efficacy of a 3-month course is under evaluation, especially for patients with clearance of HCV viremia within the first 4 weeks of therapy. There is no evidence that Peg-IFN/ribavirin combination therapy is more effective than Peg- IFN monotherapy, thus combination therapy might represent an alternative for patients who do not respond to IFN monotherapy or for HIV/HCV co-infected patients. Ongoing randomized controlled clinical trials should focus on unresolved questions and definitely establish the optimal treatment for acute hepatitis C.
Export Options
About this article
Cite this article as:
Santantonio T. and Fasano M., Therapy of Acute Hepatitis C: A Review of Literature, Current Pharmaceutical Design 2008; 14 (17) . https://dx.doi.org/10.2174/138161208784746851
DOI https://dx.doi.org/10.2174/138161208784746851 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery Theaflavin Enriched Black Tea Extract Alleviates Diabetic Nephropathy by Suppressing Hyperglycaemia-Mediated Oxidative Stress and Inflammation in Streptozotocin-Induced Rats
The Natural Products Journal Effects of Gene and Plasma Tau on Cognitive Impairment in Rural Chinese Population
Current Alzheimer Research NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway
Current Neurovascular Research Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Recent Progress in the Development of Subtype Selective Nicotinic Acetylcholine Receptor Ligands
Current Drug Targets - CNS & Neurological Disorders Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Novel Strategies to Target Inflammatory Processes in Atherosclerosis
Current Pharmaceutical Design Mesenchymal Stem Cell Research in Veterinary Medicine
Current Stem Cell Research & Therapy Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Work Related Asthma in the Textile Industry
Recent Patents on Inflammation & Allergy Drug Discovery Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Preface [Hot Topic: Novel and Alternative Non-Steroidal Treatments for Asthmatic Inflammation (Guest Editor: Mario Cazzola)]
Current Drug Targets - Inflammation & Allergy The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research
Current Medicinal Chemistry The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery